# Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC

> **NCT04459468** · — · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 17 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lipiodol

## Key facts

- **NCT ID:** NCT04459468
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-04
- **Primary completion:** 2025-09-23
- **Final completion:** 2025-09-23
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04459468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04459468, "Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT04459468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*